Association between Heparin Dose and 6-Week Mortality in Patients with COVID-19.

ABSTRACT:

Background

Severe forms of SARS-CoV-2 infections are associated with high rates of thromboembolic complications. Professional societies and expert consensus reports have recommended anticoagulants for COVID-19 hospitalized patients. Our study aimed to compare the effect of therapeutic, intermediate and prophylactic doses of heparin on 6-week survival in patients hospitalized for COVID-19.

Methods

The study sample is a French cohort of COVID-19 patients hospitalized between Feb 25th and Apr 30th 2020. Patients were assigned to one of 3 anticoagulation dose groups based on the maximum dose they received for at least three days (prophylactic, intermediate or therapeutic). The main outcome was survival up to 42 days after hospital admission. Multivariate Cox regression models we

SUBMITTER: Coutureau C 

PROVIDER: S-EPMC9083941 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature